Tris Pharma

76 articles with Tris Pharma

• Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation

  7/27/2022

  Tris Pharma, Inc. ("Tris"), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that it has successfully developed an oxybate formulation for the treatment of cataplexy.

• Tris Pharma Announces Publication of Study Results Highlighting the Efficacy and Safety of DYANAVEL® XR (amphetamine) Tablets for the Treatment of the Symptoms of ADHD in Adults

  7/22/2022

  Tris Pharma, Inc. ("Tris"), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced the publication of a Phase 3 study in the Journal of Clinical Psychiatry that demonstrated that adult patients with ADHD who took DYANAVEL XR.

• Tris Pharma announces U.S. Court of Appeals for the Federal Circuit Affirms Validity of Quillivant XR® Patents; Rules Teva Infringes Tris Patents

  7/20/2022

  Tris Pharma, Inc. ("Tris"), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision on July 7, 2022 upholding the validity and infringement of various patents relating to Quillivant XR ®.

• Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD

  11/5/2021

  Tris Pharma, Inc. (Tris) announced today that the U.S. Food and Drug Administration has approved Dyanavel XR (amphetamine) for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

• Tris Pharma® Hires Seasoned Business Development Executive

  10/7/2021

  Tris Pharma, Inc. today announced that Anthony Amato has joined the company as Executive Vice President Business Development – Generics Division. 

• Tris Pharma® Announces Acquisition of Park Therapeutics - Pain Company with First-In-Class, Phase III-Ready New Chemical Entity (NCE)

  4/29/2021

  - Novel mechanism of action, highly differentiated safety profile, 2000+ subjects studied in 27 clinical trials across Europe and US; FDA Fast Track status granted - NCE has potential to addresses significantly under-served market comprising acute and chronic pain, central and peripheral neuropathy, cancer pain, and addiction treatment

• Tris Pharma and Athena Bioscience Announce Exclusive License Agreement to Commercialize Near-to-Market Long-Acting Antihypertensive Product in the U.S.

  2/22/2021

   Tris Pharma, Inc. ("Tris") and Athena Bioscience LLC ("Athena") announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using  Tris' proprietary technology.

• Tris Pharma to Debut Amphetamine Extended-Release Tablet Efficacy and Safety Data at the 2021 APSARD Annual Meeting

  1/15/2021

  Tris Pharma, Inc. announced that it will present pivotal efficacy and safety data on its new amphetamine extended-release tablet at the virtual annual meeting of American Professional Society of ADHD and Related Disorders to be held from Friday, January 15 through Sunday, January 17, 2021.

• Tris Pharma Hires Seasoned Research & Development Executive

  12/18/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder

• Tris Pharma and Neuraxpharm Group Announce Partnership to Commercialize Tris' Quillivant XR and Quillichew ER in Europe

  12/8/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Neuraxpharm Group ("Neuraxpharm"), a leading European specialty pharma

• Tris Pharma and Medison Pharma Announce Exclusive License Agreement to Commercialize Tris' Quillivant XR in Israel

  11/17/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Medison Pharma ("Medison"), a leading international commercial partner for highly innovat

• Tris Pharma Launches New ADHD Portfolio Website for Patients and Caregivers

  11/10/2020

  Tris Pharma, Inc., a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the launch of a new website for patients and their caregivers.

• Tris Pharma to Present Amphetamine Extended-Release Tablet Data at the Research Pipeline Session of 2020 American Academy of Child and Adolescent Psychiatry Meeting

  10/22/2020

   Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that Amy Everitt , MS, PharmD of Tris' Medical team wi

• Tris Pharma Launches its Scientific Advisory Board

  10/6/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, successfully convened the inaugural meeting of its Scientific Advi

• Tris Pharma Launches Redesigned Website for ADHD Healthcare Professionals

  9/17/2020

  Tris Pharma, Inc. (Tris), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, announced today the launch of a redesigned website for healthcare professionals (HCPs).  This newly redesigned

• Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

  7/9/2020

   Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario a

• Tris Pharma Launches New Corporate Website

  6/25/2020

  Tris Pharma, Inc., a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the launch of a new corporate website that better embodies the company's evolving business model and strategic goals.

• Quillivant XR®, QuilliChew ER® and Dyanavel® XR are 100% Made in the U.S.A. and Remain Consistently Supplied During COVID-19 Pandemic

  3/17/2020

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, amidst the uncertainty created by the COVID-19 pandemic, reiterated its commitment to the ADHD community by assuring ADHD pat

• Tris Pharma Adds Seasoned Attorney to its Senior Leadership Team

  10/30/2019

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that Jonathan N. Provoost has joined the company as General Counsel, overseeing all of its legal functions.

• Tris Pharma Strengthens Its Branded Commercial Leadership Team

  9/4/2019

  Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the addition of two industry veterans to join its growing branded business